Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE R GONZALEZ CHAVEZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1619930682
CMS profile
254581
Location
SAN JUAN, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$70,903.06

183 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $34,099.69 36
E.R. Squibb & Sons, L.L.C. $8,848.11 14
ABBVIE INC. $7,911.82 30
Amgen Inc. $7,351.99 10
Lilly USA, LLC $7,318.71 5
Eli Lilly and Company $3,450.00 2
Janssen Pharmaceuticals, Inc $533.68 24
Novartis Pharmaceuticals Corporation $469.35 25
LEO Pharma Inc. $380.94 17
Eli Lilly Export S.A. Puerto Rico Branch $221.46 10
UCB, Inc. $161.06 2
PBG PUERTO RICO LLC $91.73 4
Organon LLC $64.52 4

Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE R GONZALEZ CHAVEZ

NPI 1619930682 · CMS profile ID 254581

Allopathic & Osteopathic Physicians / Dermatology

SAN JUAN, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619930682?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE R GONZALEZ CHAVEZ, NPI 1619930682, CMS profile ID 254581. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619930682?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOSE R GONZALEZ CHAVEZ, NPI 1619930682, CMS profile ID 254581. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619930682?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOSE R GONZALEZ CHAVEZ, NPI 1619930682, CMS profile ID 254581, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–183 of 183 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1619930682?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

183 matching records · $70,903.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 183 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–183 of 183.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $22.3603/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886869169 CMS
Novartis Pharmaceuticals Corporation $18.9403/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893708841 CMS
Eli Lilly Export S.A. Puerto Rico Branch $25.0003/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918107157 CMS
PBG PUERTO RICO LLC $23.8903/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949630991 CMS
Novartis Pharmaceuticals Corporation $16.9803/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893708839 CMS
E.R. Squibb & Sons, L.L.C. $10.6503/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932897741 CMS
Organon LLC $20.0003/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946431205 CMS
Janssen Pharmaceuticals, Inc $7.2002/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886869173 CMS
Novartis Pharmaceuticals Corporation $23.7502/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893708837 CMS
ABBVIE INC. $25.5502/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892667539 CMS
GENZYME CORPORATION $124.1902/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938809257 CMS
GENZYME CORPORATION $4,383.6002/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938809259 CMS
GENZYME CORPORATION $793.1002/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938809261 CMS
GENZYME CORPORATION $25.0002/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938809187 CMS
UCB, Inc. $28.5702/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908005455 CMS
UCB, Inc. $132.4902/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908005457 CMS
LEO Pharma Inc. $27.7102/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936222183 CMS
Janssen Pharmaceuticals, Inc $28.8502/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886869149 CMS
GENZYME CORPORATION $25.0002/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938809191 CMS
Novartis Pharmaceuticals Corporation $18.9402/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893708835 CMS
Amgen Inc. $1,200.0002/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939951187 CMS
E.R. Squibb & Sons, L.L.C. $7.8402/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932897733 CMS
Novartis Pharmaceuticals Corporation $20.7302/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893708833 CMS
ABBVIE INC. $2.4101/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892667537 CMS
GENZYME CORPORATION $4.1501/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938809175 CMS
LEO Pharma Inc. $24.5201/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936222179 CMS
Novartis Pharmaceuticals Corporation $21.3601/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893708829 CMS
ABBVIE INC. $24.3001/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892667535 CMS
Janssen Pharmaceuticals, Inc $6.2901/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886869181 CMS
Novartis Pharmaceuticals Corporation $17.6501/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893708831 CMS
Janssen Pharmaceuticals, Inc $25.5701/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886869175 CMS
LEO Pharma Inc. $30.7901/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936222175 CMS
Novartis Pharmaceuticals Corporation $14.2101/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893708827 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $61,191.44 164
PY2020 $17,205.43 67
PY2021 $38,155.71 131
PY2022 $70,903.06 183
PY2023 $52,495.82 148
PY2024 $2,824.24 113
PY2025 $4,855.21 100

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $715,894.02 101
PY2024 Recipient $104.58 1
PY2024 Principal investigator $557,835.53 79
PY2023 Principal investigator $211,603.39 73
PY2022 Recipient $1,665.00 2
PY2022 Principal investigator $188,895.32 75
PY2021 Recipient $17,558.77 3
PY2021 Principal investigator $754,611.65 68
PY2020 Recipient $2,933.25 3
PY2020 Principal investigator $668,450.18 52
PY2019 Recipient $37,426.34 13
PY2019 Principal investigator $1,349,911.43 32

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

101 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
SAN JUAN MED
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202534797
Principal investigator 1 UCB SA $2,853.80 12/26/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246656876
Principal investigator 1 UCB SA $1,891.45 12/26/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246656880
Principal investigator 1 ABBVIE INC. $2,125.00 12/18/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202531140
Principal investigator 1 ABBVIE INC. $425.00 12/18/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202531142
Principal investigator 1 ABBVIE INC. $1,200.00 12/18/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202531144
Principal investigator 1 ABBVIE INC. $1,000.00 12/11/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202530004
Principal investigator 1 ABBVIE INC. $6,529.46 12/04/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202526926
Principal investigator 1 ABBVIE INC. $3,998.38 12/04/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202527018
Principal investigator 1 ABBVIE INC. $64,199.16 11/26/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202525500
Principal investigator 1 UCB SA $90.00 11/24/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658838
Principal investigator 1 UCB SA $2,000.00 11/24/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658868
Principal investigator 1 UCB SA $500.00 11/24/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658870
Principal investigator 1 ABBVIE INC. $50.00 11/06/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202523309
Principal investigator 1 ABBVIE INC. $125.00 11/06/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202523445
Principal investigator 1 ABBVIE INC. $1,025.00 11/06/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202523447
Principal investigator 1 ABBVIE INC. $3,305.58 11/05/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202521987
Principal investigator 1 ABBVIE INC. $500.00 11/05/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202521989
Principal investigator 1 ABBVIE INC. $18,949.86 11/05/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522059
Principal investigator 1 ABBVIE INC. $2,147.24 11/04/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202520451
Principal investigator 1 ABBVIE INC. $300.00 10/28/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202518833
Principal investigator 1 ABBVIE INC. $1,150.00 10/17/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202517429
Principal investigator 1 ABBVIE INC. $1,572.50 10/09/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202515477
Principal investigator 1 ABBVIE INC. $4,246.18 10/09/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202515479
Principal investigator 1 ABBVIE INC. $5,450.00 10/09/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515497
Principal investigator 1 ABBVIE INC. $5,239.16 10/09/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202516179
Principal investigator 1 UCB SA $1,891.45 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658050
Principal investigator 1 UCB SA $2,853.80 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658052
Principal investigator 1 UCB SA $2,378.80 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658054
Principal investigator 1 UCB SA $1,964.00 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658056
Principal investigator 1 UCB SA $198.55 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658058
Principal investigator 1 UCB SA $519.65 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658060
Principal investigator 1 UCB SA $519.65 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658064
Principal investigator 1 UCB SA $23,573.95 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658066
Principal investigator 1 UCB SA $519.65 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658068
Principal investigator 1 UCB SA $519.65 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658070
Principal investigator 1 UCB SA $519.65 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658072
Principal investigator 1 UCB SA $1,975.05 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658074
Principal investigator 1 UCB SA $2,378.80 10/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) No dispute reported 06/30/2026 1246658076
Principal investigator 1 ABBVIE INC. $1,000.00 09/17/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202511254
Principal investigator 1 ABBVIE INC. $822.50 09/17/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202511256
Principal investigator 1 ABBVIE INC. $50.00 09/16/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202510980
Principal investigator 1 ABBVIE INC. $101.25 09/16/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202510982
Principal investigator 1 ABBVIE INC. $172.50 09/11/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202510596
Principal investigator 1 ABBVIE INC. $10,133.05 09/04/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202508448
Principal investigator 1 ABBVIE INC. $9,078.68 09/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202508292
Principal investigator 1 ABBVIE INC. $1,000.00 08/14/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202504705
Principal investigator 1 ABBVIE INC. $7,000.00 08/14/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202504707
Principal investigator 1 ABBVIE INC. $25.00 08/14/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202504709
Principal investigator 1 ABBVIE INC. $8,800.00 08/12/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202504237
Principal investigator 1 ABBVIE INC. $783.75 07/24/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202499562
Principal investigator 1 ABBVIE INC. $1,650.00 07/14/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202498158
Principal investigator 1 ABBVIE INC. $75.00 07/10/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202497966
Principal investigator 1 ABBVIE INC. $375.00 07/09/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202497602
Principal investigator 1 ABBVIE INC. $2,190.62 07/08/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497150
Principal investigator 1 ABBVIE INC. $4,836.00 07/08/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497192
Principal investigator 1 ABBVIE INC. $157.48 07/02/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202494909
Principal investigator 1 ABBVIE INC. $3,867.16 07/02/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495013
Principal investigator 1 ABBVIE INC. $7,848.47 07/02/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495015
Principal investigator 1 ABBVIE INC. $1,000.00 06/18/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202492095
Principal investigator 1 ABBVIE INC. $172.50 06/17/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202491715
Principal investigator 1 SANOFI US SERVICES INC. $650.00 06/09/2025 Non-covered Recipient Entity
Gcm Medical Group PSC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226135160
Principal investigator 1 ABBVIE INC. $5,209.98 06/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202487679
Principal investigator 1 ABBVIE INC. $3,796.30 06/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202487681
Principal investigator 1 ABBVIE INC. $4,836.00 06/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202487683
Principal investigator 1 ABBVIE INC. $3,998.38 06/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202488727
Principal investigator 1 ABBVIE INC. $533.75 05/14/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202484811
Principal investigator 1 ABBVIE INC. $175.00 05/08/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202484275
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $25,382.00 05/08/2025 Non-covered Recipient Entity
Gcm Medical Group
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997187
Principal investigator 1 ABBVIE INC. $3,305.58 05/07/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202482621
Principal investigator 1 ABBVIE INC. $9,162.26 05/07/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482731
Principal investigator 1 ABBVIE INC. $900.00 05/06/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202481251
Principal investigator 1 ABBVIE INC. $4,995.48 05/06/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202481365
Principal investigator 1 ABBVIE INC. $4,800.00 04/15/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202476501
Principal investigator 1 ABBVIE INC. $33.75 04/10/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202475781
Principal investigator 1 ABBVIE INC. $21,385.00 04/09/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202475091
Principal investigator 1 SANOFI US SERVICES INC. $20,500.00 04/07/2025 Non-covered Recipient Entity
Gcm Medical Group PSC
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226135114
Principal investigator 1 ABBVIE INC. $4,395.78 04/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202469727
Principal investigator 1 ABBVIE INC. $3,706.64 04/03/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202471615
Principal investigator 1 Amgen Inc. $31,311.80 03/25/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246641729
Principal investigator 1 ABBVIE INC. $2,935.28 03/13/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202463637
Principal investigator 1 ABBVIE INC. $67.50 03/13/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202463730
Principal investigator 1 Eli Lilly and Company $1,230.27 03/10/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187883458
Principal investigator 1 ABBVIE INC. $4,775.38 03/07/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202461768
Principal investigator 1 ABBVIE INC. $10,038.18 03/07/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202462094
Principal investigator 1 ABBVIE INC. $664.00 02/24/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202453624
Principal investigator 1 ABBVIE INC. $2,615.58 02/20/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202452899
Principal investigator 1 ABBVIE INC. $4,800.00 02/13/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202451181
Principal investigator 1 ABBVIE INC. $260.00 02/12/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202450824
Principal investigator 1 ABBVIE INC. $135.00 02/12/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202450829
Principal investigator 1 ABBVIE INC. $19,546.71 02/06/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202447749
Principal investigator 1 ABBVIE INC. $19,568.87 02/06/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202447887
Principal investigator 1 ABBVIE INC. $18,500.00 02/06/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202447898
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $91,957.00 01/30/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187881868
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $55.02 01/27/2025 Non-covered Recipient Entity
Gcm Medical Group
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997189
Principal investigator 1 Eli Lilly and Company $3,929.30 01/27/2025 Covered Recipient Teaching Hospital
DRISCOLL CHILDRENS HOSPITAL
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187872407
Principal investigator 1 Amgen Inc. $46,871.15 01/22/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246641732
Principal investigator 1 ABBVIE INC. $953.80 01/20/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202440067
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $91,568.00 01/16/2025 Non-covered Recipient Entity
Gcm Medical Group Psc
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997185
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $12,750.00 01/16/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187882802
Principal investigator 1 ABBVIE INC. $241.50 01/14/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202438314